María Belén Zanchetta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
María Belén Zanchetta has a total of 260 co-authors. Here are the top co-authors by number of shared publications:
Fernando Jerkovich
Instituto de Diagnóstico e Investigaciones Metabólicas (IDIM), ZP 1012, Buenos Aires, Argentina
5 shared publications- Fernando Jerkovich
Division of Endocrinology, Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina
5 shared publications Vanesa Longobardi
Instituto de Diagnóstico e Investigaciones Metabólicas (IDIM), Buenos Aires, Argentina
5 shared publicationsFernando Silveira
Instituto de Diagnóstico e Investigaciones Metabólicas (IDIM), Buenos Aires, Argentina
4 shared publicationsJosé Rubén Zanchetta
Instituto de Diagnóstico e Investigaciones Metabólicas (IDIM), ZP 1012, Buenos Aires, Argentina
4 shared publications- Ruben Abdala
Instituto de Diagnóstico e Investigaciones Metabólicas, Buenos Aires, Argentina.
4 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Springer Nature in Calcified Tissue International
- Vol. 117 (1) , 126
Burden of Disease in Pediatric Tumor-Induced Osteomalacia: A Literature Review
Tumor-induced osteomalacia (TIO) is an ultra-rare, paraneoplastic syndrome caused by tumors secreting fibroblast growth factor 23 (FGF23). In children, TIO may be mistaken for more common causes of rickets and osteomalacia, including monogenic forms, leading to long diagnostic delays. This review aimed to identify evidence on the diagnostic journey and burden of TIO in pediatric patients. A literature review was conducted to identify publications reporting disease characteristics, investigations, treatments, and clinical outcomes in pediatric patients diagnosed with TIO. In total, 41 studies were included in the review, reporting on 46 pediatric patients. Mean age at presentation was 11.2 years (standard deviation [SD]: 4.6). The majority of individuals (60.9%) were male. The most commonly reported symptoms at presentation were pain (65.2%), weakness (47.8%), and impaired physical function (43.5%). Rickets was reported in 45.7% of patients and fractures in 34.8% of patients. Mean time from onset of symptoms to diagnosis was 4.3 years (SD: 2.6) and mean number of imaging procedures per patient was 5.4 (SD: 2.7). Low serum phosphate concentration for age was reported in 93.5% of patients at presentation. Attempted surgical resection was reported in the majority of patients (89.1%) and was successful in 60.9%. Pediatric-onset TIO is associated with a substantial symptomatic and healthcare burden. Increasing awareness of TIO in children may prevent delays in diagnosis, reduce the need for radiation-conferring tests, and lower morbidity due to effective management. Further research in this area is needed to address the scarcity of data available in pediatric patients.
- 10 August 2026
- Published by Springer Nature in Calcified Tissue International
- Vol. 117 (1) , 126
Open AccessBurden of Disease in Pediatric Tumor-Induced Osteomalacia: A Literature Review
Tumor-induced osteomalacia (TIO) is an ultra-rare, paraneoplastic syndrome caused by tumors secreting fibroblast growth factor 23 (FGF23). In children, TIO may be mistaken for more common causes of rickets and osteomalacia, including monogenic forms, leading to long diagnostic delays. This review aimed to identify evidence on the diagnostic journey and burden of TIO in pediatric patients. A literature review was conducted to identify publications reporting disease characteristics, investigations, treatments, and clinical outcomes in pediatric patients diagnosed with TIO. In total, 41 studies were included in the review, reporting on 46 pediatric patients. Mean age at presentation was 11.2 years (standard deviation [SD]: 4.6). The majority of individuals (60.9%) were male. The most commonly reported symptoms at presentation were pain (65.2%), weakness (47.8%), and impaired physical function (43.5%). Rickets was reported in 45.7% of patients and fractures in 34.8% of patients. Mean time from onset of symptoms to diagnosis was 4.3 years (SD: 2.6) and mean number of imaging procedures per patient was 5.4 (SD: 2.7). Low serum phosphate concentration for age was reported in 93.5% of patients at presentation. Attempted surgical resection was reported in the majority of patients (89.1%) and was successful in 60.9%. Pediatric-onset TIO is associated with a substantial symptomatic and healthcare burden. Increasing awareness of TIO in children may prevent delays in diagnosis, reduce the need for radiation-conferring tests, and lower morbidity due to effective management. Further research in this area is needed to address the scarcity of data available in pediatric patients.
- Open Access
- 27 July 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (9)
Real-world outcomes in patients with tumor-induced osteomalacia treated vs not treated with burosumab
Context: Tumor-induced osteomalacia (TIO) is an ultra-rare condition caused by tumors secreting fibroblast growth factor-23, leading to chronic hypophosphatemia, pain, muscle weakness, fractures, and impaired physical function. Burosumab is a monoclonal antibody indicated for treatment of TIO when tumors cannot be curatively resected. Objective: This study compares clinical and patient-reported outcomes in patients with TIO treated vs not treated with burosumab in a real-world setting. Design: This interim analysis reports outcomes at enrollment in the prospective, observational Tumor-Induced Osteomalacia Disease Monitoring Program (NCT04783428), stratified by burosumab treatment status at enrollment. Setting: Tertiary care centers in the United States and Argentina. Patients: Patients with TIO from the Disease Monitoring Program. Exposure: Burosumab treatment. Main outcome measure(s): Biochemistry measurements and patient-reported health-related quality of life (pain, fatigue, and physical function). Results: 21 patients with TIO (61.9% female, median [Q1, Q3] age 49.7 years [41.6, 57.3]) were included. At enrollment, 11 (52.4%) patients were treated with burosumab, for a median (Q1, Q3) duration of 4.1 years (0.8, 7.0). Burosumab-treated patients had significantly higher serum phosphate and 1,25-dihydroxyvitamin D levels, and nonsignificantly lower alkaline phosphatase levels, compared with patients not treated with burosumab. Patients treated with burosumab reported significantly lower median Brief Pain Inventory scores, nonsignificantly lower Brief Fatigue Inventory scores, and nonsignificantly higher Patient-Reported Outcomes Measurement Information System Physical Function and Short-Form-36 scores, indicating lower symptom severity and better health-related quality of life. Conclusion: This study suggests favorable biochemical and patient-reported outcomes in patients with TIO treated with burosumab.
- 27 July 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (9)
Open AccessReal-world outcomes in patients with tumor-induced osteomalacia treated vs not treated with burosumab
Context: Tumor-induced osteomalacia (TIO) is an ultra-rare condition caused by tumors secreting fibroblast growth factor-23, leading to chronic hypophosphatemia, pain, muscle weakness, fractures, and impaired physical function. Burosumab is a monoclonal antibody indicated for treatment of TIO when tumors cannot be curatively resected. Objective: This study compares clinical and patient-reported outcomes in patients with TIO treated vs not treated with burosumab in a real-world setting. Design: This interim analysis reports outcomes at enrollment in the prospective, observational Tumor-Induced Osteomalacia Disease Monitoring Program (NCT04783428), stratified by burosumab treatment status at enrollment. Setting: Tertiary care centers in the United States and Argentina. Patients: Patients with TIO from the Disease Monitoring Program. Exposure: Burosumab treatment. Main outcome measure(s): Biochemistry measurements and patient-reported health-related quality of life (pain, fatigue, and physical function). Results: 21 patients with TIO (61.9% female, median [Q1, Q3] age 49.7 years [41.6, 57.3]) were included. At enrollment, 11 (52.4%) patients were treated with burosumab, for a median (Q1, Q3) duration of 4.1 years (0.8, 7.0). Burosumab-treated patients had significantly higher serum phosphate and 1,25-dihydroxyvitamin D levels, and nonsignificantly lower alkaline phosphatase levels, compared with patients not treated with burosumab. Patients treated with burosumab reported significantly lower median Brief Pain Inventory scores, nonsignificantly lower Brief Fatigue Inventory scores, and nonsignificantly higher Patient-Reported Outcomes Measurement Information System Physical Function and Short-Form-36 scores, indicating lower symptom severity and better health-related quality of life. Conclusion: This study suggests favorable biochemical and patient-reported outcomes in patients with TIO treated with burosumab.
- 11 July 2026
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 29 (4)
Impact of vertebral exclusion on precision error and least significant change in Trabecular Bone Score measurement
- 11 July 2026
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 29 (4)
Impact of vertebral exclusion on precision error and least significant change in Trabecular Bone Score measurement
- Open Access
- 27 January 2026
- Published by Elsevier in Bone Reports
- Vol. 28, 101902
Assessing cortical bone changes with Romosozumab after one year: Insights from an exploratory HR-pQCT study
- 27 January 2026
- Published by Elsevier in Bone Reports
- Vol. 28, 101902
Open AccessAssessing cortical bone changes with Romosozumab after one year: Insights from an exploratory HR-pQCT study
- Open Access
- 8 December 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (2)
Romosozumab after rebound vertebral fractures induced by denosumab discontinuation: a case series
Introduction: Discontinuation of denosumab can lead to a rebound increase in bone resorption, which may result in multiple vertebral fractures. Current guidelines recommend retreatment with denosumab or administration of zoledronate in this setting. Materials and methods: We report a series of 4 patients who developed vertebral fractures following denosumab withdrawal and were subsequently treated with romosozumab, a dual-action agent with anabolic and antiresorptive properties. Results: All patients showed progressive improvement in BMD and microarchitecture, with suppression of bone turnover markers and no new clinical fractures during treatment and follow-up. Discussion: Although limited by the uncontrolled design and small sample size, these observations suggest that romosozumab might be considered as a potential therapeutic approach for selected patients with post-denosumab rebound fractures.
- 8 December 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (2)
Open AccessRomosozumab after rebound vertebral fractures induced by denosumab discontinuation: a case series
Introduction: Discontinuation of denosumab can lead to a rebound increase in bone resorption, which may result in multiple vertebral fractures. Current guidelines recommend retreatment with denosumab or administration of zoledronate in this setting. Materials and methods: We report a series of 4 patients who developed vertebral fractures following denosumab withdrawal and were subsequently treated with romosozumab, a dual-action agent with anabolic and antiresorptive properties. Results: All patients showed progressive improvement in BMD and microarchitecture, with suppression of bone turnover markers and no new clinical fractures during treatment and follow-up. Discussion: Although limited by the uncontrolled design and small sample size, these observations suggest that romosozumab might be considered as a potential therapeutic approach for selected patients with post-denosumab rebound fractures.
- Open Access
- 31 October 2025
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 24 (1) , 15-21
⁶⁸Ga-DOTATATE PET/CT Findings in Suspected Tumor-Induced Osteomalacia
Objective. To describe ⁶⁸Ga-DOTATATE PET/CT findings and their relationship to available histopathology in patients referred for suspected tumor-induced osteomalacia. Methods. This prospective descriptive study included 18 patients evaluated at a referral center in Argentina. Results. The median age was 47.5 years and 13 of 18 patients were women. The reported median SUVmax was 17.2 (interquartile range 6.27–30.6). Lesions were most frequently reported in the appendicular skeleton. Eight patients had histologically confirmed phosphaturic mesenchymal tumors (PMTs). Two of these eight patients had lesions with ill-defined margins and involvement of soft tissue and facial bones. Median SUVmax was numerically higher in the PMT group. The difference was not statistically significant as reported. Conclusion. In this referral cohort, ⁶⁸Ga-DOTATATE PET/CT helped localize and characterize lesions in patients with suspected tumor-induced osteomalacia. Confirmed PMTs showed variable morphology. The findings support descriptive interpretation in conjunction with histopathology and clinical assessment.
- 31 October 2025
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 24 (1) , 15-21
Open Access⁶⁸Ga-DOTATATE PET/CT Findings in Suspected Tumor-Induced Osteomalacia
Objective. To describe ⁶⁸Ga-DOTATATE PET/CT findings and their relationship to available histopathology in patients referred for suspected tumor-induced osteomalacia. Methods. This prospective descriptive study included 18 patients evaluated at a referral center in Argentina. Results. The median age was 47.5 years and 13 of 18 patients were women. The reported median SUVmax was 17.2 (interquartile range 6.27–30.6). Lesions were most frequently reported in the appendicular skeleton. Eight patients had histologically confirmed phosphaturic mesenchymal tumors (PMTs). Two of these eight patients had lesions with ill-defined margins and involvement of soft tissue and facial bones. Median SUVmax was numerically higher in the PMT group. The difference was not statistically significant as reported. Conclusion. In this referral cohort, ⁶⁸Ga-DOTATATE PET/CT helped localize and characterize lesions in patients with suspected tumor-induced osteomalacia. Confirmed PMTs showed variable morphology. The findings support descriptive interpretation in conjunction with histopathology and clinical assessment.
- 10 October 2025
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 28 (4) , 101632
Impaired bone mineral density in patients with complex regional pain syndrome
- 10 October 2025
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 28 (4) , 101632
Impaired bone mineral density in patients with complex regional pain syndrome
- Open Access
- 30 March 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 9 (5) , ziaf041
How does bone recover in patients with tumor-induced osteomalacia? Long-term follow-up in a national cohort study
Tumor-induced osteomalacia (TIO) is a rare disorder characterized by impaired bone mineralization due to phosphate wasting. Long-term changes in BMD and microarchitecture after surgical cure or medical therapy in TIO are not well understood. This study describes changes in BMD, microarchitecture, and bone strength in patients with TIO following surgical cure or medical therapy. A prospective cohort study included adults diagnosed with TIO from May 2018 to 2024, categorized into those with surgical cure and those on medical therapy. Follow-up assessments were classified as early (median 8 mo), intermediate (median 17 mo), and long-term (median 26 mo). Fifteen patients were included: seven achieved surgical cure, and eight remained on medical therapy. Lumbar spine BMD increased by +19% at early, +27% at intermediate, and +15% at long-term follow-up. Total hip BMD increased by +31%, +36%, and +31% at early, intermediate, and long-term assessments, respectively. All patients achieved a normal lumbar spine BMD, while 91% attained a normal total hip BMD. At the distal tibia, substantial increases in bone microarchitecture parameters—cortical area (Ct.Ar), cortical volumetric density (Ct.vBMD), and cortical thickness (Ct.Th)—were observed. Notably, Ct.Th improved to levels comparable to healthy controls. Bone strength improved by 13% but was not statistically significant, probably due to the small sample size. At the distal radius, most parameters remained stable. Patients with surgical cure showed more rapid and substantial improvements in BMD and cortical microarchitecture than non-cured patients, but these differences did not reach statistical significance. Overall, bone recovery in TIO is gradual, with gains in spine and hip BMD and significant improvements in tibial cortical parameters. However, some aspects of bone microarchitecture remained below control levels, underscoring the need for ongoing monitoring and individualized management strategies.
- 30 March 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 9 (5) , ziaf041
Open AccessHow does bone recover in patients with tumor-induced osteomalacia? Long-term follow-up in a national cohort study
Tumor-induced osteomalacia (TIO) is a rare disorder characterized by impaired bone mineralization due to phosphate wasting. Long-term changes in BMD and microarchitecture after surgical cure or medical therapy in TIO are not well understood. This study describes changes in BMD, microarchitecture, and bone strength in patients with TIO following surgical cure or medical therapy. A prospective cohort study included adults diagnosed with TIO from May 2018 to 2024, categorized into those with surgical cure and those on medical therapy. Follow-up assessments were classified as early (median 8 mo), intermediate (median 17 mo), and long-term (median 26 mo). Fifteen patients were included: seven achieved surgical cure, and eight remained on medical therapy. Lumbar spine BMD increased by +19% at early, +27% at intermediate, and +15% at long-term follow-up. Total hip BMD increased by +31%, +36%, and +31% at early, intermediate, and long-term assessments, respectively. All patients achieved a normal lumbar spine BMD, while 91% attained a normal total hip BMD. At the distal tibia, substantial increases in bone microarchitecture parameters—cortical area (Ct.Ar), cortical volumetric density (Ct.vBMD), and cortical thickness (Ct.Th)—were observed. Notably, Ct.Th improved to levels comparable to healthy controls. Bone strength improved by 13% but was not statistically significant, probably due to the small sample size. At the distal radius, most parameters remained stable. Patients with surgical cure showed more rapid and substantial improvements in BMD and cortical microarchitecture than non-cured patients, but these differences did not reach statistical significance. Overall, bone recovery in TIO is gradual, with gains in spine and hip BMD and significant improvements in tibial cortical parameters. However, some aspects of bone microarchitecture remained below control levels, underscoring the need for ongoing monitoring and individualized management strategies.
- Open Access
- 14 January 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (2) , 175
Comparison of Resampling Methods and Radiomic Machine Learning Classifiers for Predicting Bone Quality Using Dual-Energy X-Ray Absorptiometry
Background/Objectives: This study presents a novel approach, based on a combination of radiomic feature extraction, data resampling techniques, and machine learning algorithms, for the detection of degraded bone structures in Dual X-ray Absorptiometry (DXA) images. This comprehensive approach, which addresses the critical aspects of the problem, distinguishes this work from previous studies, improving the performance achieved by the most similar studies. The primary aim is to provide clinicians with an accessible tool for quality bone assessment, which is currently limited. Methods: A dataset of 1531 spine DXA images was automatically segmented and labelled based on Trabecular Bone Score (TBS) values. Radiomic features were extracted using Pyradiomics, and various resampling techniques were employed to address class imbalance. Three machine learning classifiers (Logistic Regression, Support Vector Machine (SVM), and XGBoost) were trained and evaluated using standard performance metrics. Results: The SVM classifier outperformed the other classifiers. The highest F-score of 97.5% was achieved using the Grey Level Dependence Matrix and Grey Level Run Length Matrix feature combination with SMOTEENN resampling, which proved to be the most effective resampling technique, while the undersampling method yielded the lowest performance. Conclusions: This research demonstrates the potential of radiomic texture features, resampling techniques, and machine learning methods for classifying DXA images into healthy or degraded bone structures, which potentially leads to improved clinical diagnosis and treatment.
- 14 January 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (2) , 175
Open AccessComparison of Resampling Methods and Radiomic Machine Learning Classifiers for Predicting Bone Quality Using Dual-Energy X-Ray Absorptiometry
Background/Objectives: This study presents a novel approach, based on a combination of radiomic feature extraction, data resampling techniques, and machine learning algorithms, for the detection of degraded bone structures in Dual X-ray Absorptiometry (DXA) images. This comprehensive approach, which addresses the critical aspects of the problem, distinguishes this work from previous studies, improving the performance achieved by the most similar studies. The primary aim is to provide clinicians with an accessible tool for quality bone assessment, which is currently limited. Methods: A dataset of 1531 spine DXA images was automatically segmented and labelled based on Trabecular Bone Score (TBS) values. Radiomic features were extracted using Pyradiomics, and various resampling techniques were employed to address class imbalance. Three machine learning classifiers (Logistic Regression, Support Vector Machine (SVM), and XGBoost) were trained and evaluated using standard performance metrics. Results: The SVM classifier outperformed the other classifiers. The highest F-score of 97.5% was achieved using the Grey Level Dependence Matrix and Grey Level Run Length Matrix feature combination with SMOTEENN resampling, which proved to be the most effective resampling technique, while the undersampling method yielded the lowest performance. Conclusions: This research demonstrates the potential of radiomic texture features, resampling techniques, and machine learning methods for classifying DXA images into healthy or degraded bone structures, which potentially leads to improved clinical diagnosis and treatment.
- Open Access
- 30 November 2024
- Published by Korean Society for Bone and Mineral Research in Journal of Bone Metabolism
- Vol. 31 (4) , 279-289
Age- and Sex-Related Volumetric Density Differences in Trabecular and Cortical Bone of the Proximal Femur in Healthy Population
Background: There are age- and sex-related increases in the prevalence of osteoporosis. Bone densitometry based on dual energy X-ray absorptiometry (DXA) is the gold standard for the assessment of bone mineral density (BMD). Three-dimensional (3D) analysis of the proximal femur (3D-DXA) allows discrimination between cortical and trabecular compartments, and it has shown a good correlation with computed tomography. We aimed to assess age- and sex-related volumetric density differences in trabecular and cortical bone using 3D-DXA and determine the reference intervals for integral volumetric (v)BMD within the Argentine population.Methods: Healthy female and male adult subjects (N=1,354) from Argentina were included. Hip BMD was measured using DXA, and 3D analysis was performed using 3D-Shaper software. The integral vBMD, cortical surface BMD, and trabecular vBMD (trab vBMD) were measured.Results: The study population included 73.9% women (N=1,001) and 26.13% men (N=353). We found a significant decrease in integral vBMD between 20 and 90 years in both sexes (women, -23.1%; men, -16.6%). Bone loss indicated in the integral vBMD results was mainly due to a decrease in trabecular bone in both sexes (women, -33.4%; men, -27.7%). The age-related loss of cortical bone density was less and was limited to the female population, without no age-related differences in men. Moreover, 3D-DXA allowed us to propose reference intervals for integral vBMD.Conclusions: We found age- and sex-related bone loss between 20 and 90 years in an Argentine cohort via integral vBMD measurements using 3D-DXA, mainly due to decreases in trabecular bone in both sexes. The age-related loss of cortical bone density was less and was limited to the female population.
- 30 November 2024
- Published by Korean Society for Bone and Mineral Research in Journal of Bone Metabolism
- Vol. 31 (4) , 279-289
Open AccessAge- and Sex-Related Volumetric Density Differences in Trabecular and Cortical Bone of the Proximal Femur in Healthy Population
Background: There are age- and sex-related increases in the prevalence of osteoporosis. Bone densitometry based on dual energy X-ray absorptiometry (DXA) is the gold standard for the assessment of bone mineral density (BMD). Three-dimensional (3D) analysis of the proximal femur (3D-DXA) allows discrimination between cortical and trabecular compartments, and it has shown a good correlation with computed tomography. We aimed to assess age- and sex-related volumetric density differences in trabecular and cortical bone using 3D-DXA and determine the reference intervals for integral volumetric (v)BMD within the Argentine population.Methods: Healthy female and male adult subjects (N=1,354) from Argentina were included. Hip BMD was measured using DXA, and 3D analysis was performed using 3D-Shaper software. The integral vBMD, cortical surface BMD, and trabecular vBMD (trab vBMD) were measured.Results: The study population included 73.9% women (N=1,001) and 26.13% men (N=353). We found a significant decrease in integral vBMD between 20 and 90 years in both sexes (women, -23.1%; men, -16.6%). Bone loss indicated in the integral vBMD results was mainly due to a decrease in trabecular bone in both sexes (women, -33.4%; men, -27.7%). The age-related loss of cortical bone density was less and was limited to the female population, without no age-related differences in men. Moreover, 3D-DXA allowed us to propose reference intervals for integral vBMD.Conclusions: We found age- and sex-related bone loss between 20 and 90 years in an Argentine cohort via integral vBMD measurements using 3D-DXA, mainly due to decreases in trabecular bone in both sexes. The age-related loss of cortical bone density was less and was limited to the female population.